Analysis Ajanta Pharma Limited (AJANTPHARM)
6/1/2024
Analysis of Ajanta Pharma Limited (AJANTPHARM)
Ajanta Pharma Limited has been showing a slightly bearish trend in the recent days. The Relative Strength Index (RSI) is hovering around 48.26, indicating a neutral sentiment. The Moving Average Convergence Divergence (MACD) histogram is negative, suggesting a bearish momentum.The stock price has been fluctuating around the Simple Moving Average (SMA) and Exponential Moving Average (EMA), indicating a lack of clear direction. The Weighted Moving Average (WMA) is also showing a similar pattern.
Overall, Ajanta Pharma Limited seems to be in a consolidation phase with no strong bullish or bearish signals. Traders and investors may want to wait for a clearer trend to emerge before making any significant trading decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for the company in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the near term compared to the past 5 years. However, the company is still expected to maintain a healthy growth rate over the next year and the next 5 years according to analyst consensus.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast of $200. However, it's worth noting that there is a wide range of forecasts, from a low of $164 to a high of $250. The current price of the security is $191.57, which is below both the average and median forecasted prices.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results on February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at a specific time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The company's financials show a strong cash flow, with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet indicates a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31%, with a return on assets of 22.07% and return on equity of 147.25%. The fiscal year ends on September 30, 2023, with a most recent quarter ending on March 31, 2024.In terms of income statement, the company has an EBITDA of $131.39 billion, revenue of $381.62 billion, and a net income to common of $100.39 billion. The diluted EPS is $6.43, with a gross profit of $169.15 billion. The company experienced a negative quarterly revenue growth of -4.3% and a negative quarterly earnings growth year over year of -2.2%.
The stock statistics show a short ratio of 1.53, with 15.31 billion float shares and 99.29 million shares shorted. The company has 15.33 billion shares outstanding, with 5.22% held by insiders and 57.59% held by institutions. The short percent of shares outstanding is 0.65%.
Valuation metrics include a PEG ratio of 26.32, forward PE of 26.32, and trailing PE of 29.59. The enterprise value is $2.95 trillion, with a price to book ratio of 39.34 and price to sales ratio of 7.65. The enterprise to EBITDA ratio is 22.76, and the enterprise to revenue ratio is 7.73. The market capitalization is $2.92 trillion.
The stock price summary shows a beta of 1.26, with a 50-day moving average of $176.26 and a 200-day moving average of $181.04. The fifty-two-week low is $164.08, the high is $199.62, and the change is 6.85%.
In terms of dividends and splits, the company has a payout ratio of 14.93% and a forward annual dividend rate of 1. The 5-year average dividend yield is 0.73%, with a forward annual dividend yield of 0.53% and a trailing annual dividend yield of 0.51%. The dividend date is May 16, 2024, with an ex-dividend date of May 10, 2024. The last split date was on August 31, 2020, with a 4-for-1 split.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2023 (as of September 30, 2023):
- Sales: $383,285,000,000
2. Fiscal Year 2022 (as of September 30, 2022):
- Sales: $394,328,000,000
3. Fiscal Year 2021 (as of September 30, 2021):
- Sales: $365,817,000,000
4. Fiscal Year 2020 (as of September 30, 2020):
- Sales: $274,515,000,000
Based on the revenue figures, we can see that there has been a general upward trend in sales over the past four years, with a significant increase from 2020 to 2022, followed by a slight decrease in 2023. This indicates a positive growth trajectory for the company in terms of revenue generation.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown a positive trend, indicating a healthy financial position.
6. The company has been managing its short-term and long-term debts effectively.
7. Accumulated depreciation has been significant, affecting the value of non-current assets.
8. The company has been investing in leases, land, and improvements over the years.
9. There is a consistent provision for risks and charges in the liabilities section.
10. Overall, the company's financial health seems stable and improving over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2021.
5. Financing activities show a pattern of common stock repurchase, long-term debt issuance, and payments, with significant fluctuations in values.
6. Investing activities reflect the company's investments in acquisitions, capital expenditures, and the sale and purchase of investments.
7. Overall, the company's financial performance seems to be stable, with some fluctuations in key financial metrics over the years.
MACD of AJANTPHARM
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
